We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

The Use of Clonidine in Pain and Anxiety Associated With Acute Burn Injury in Children (clonidine)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00580151
Recruitment Status : Terminated (Closed due to no response from PI to IRB)
First Posted : December 24, 2007
Results First Posted : February 23, 2015
Last Update Posted : February 23, 2015
Information provided by (Responsible Party):

Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double (Participant, Investigator);   Primary Purpose: Treatment
Conditions: Pain
Interventions: Drug: clonidine
Drug: placebo

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Patients recruited in the medical clinic. Recruitment occured between 11/10/04-7/16/05.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
All participants were eligible to participate in the study.

Reporting Groups
Experimental Group clonidine : 3-5 microgram per kilogram every 6 hours for 10 days
Control Group placebo : 1 dose every 6 hours

Participant Flow:   Overall Study
    Experimental Group   Control Group
STARTED   9   0 
COMPLETED   9   0 

  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Experimental Group clonidine : 3-5 microgram per kilogram every 6 hours for 10 days
Control Group placebo : 1 dose every 6 hours
Total Total of all reporting groups

Baseline Measures
   Experimental Group   Control Group   Total 
Overall Participants Analyzed 
[Units: Participants]
 9   0   9 
[Units: Participants]
<=18 years   9      9 
Between 18 and 65 years   0      0 
>=65 years   0      0 
[Units: Years]
Mean (Standard Deviation)
 7.8  (3.2)      7.8  (3.2) 
[Units: Participants]
Female   1      1 
Male   8      8 
Region of Enrollment 
[Units: Participants]
United States   9      9 

  Outcome Measures

1.  Primary:   Pain Reduction   [ Time Frame: Average of the 10 days ]

2.  Secondary:   Anxiety Reduction   [ Time Frame: Average of the 10 days ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No Adverse Events Recorded.

  More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.

Results Point of Contact:  
Name/Title: Walter Meyer, M.D.
Organization: University of Texas-Galveston
phone: 409-770-6718
e-mail: wmeyer@utmb.edu

Responsible Party: The University of Texas Medical Branch, Galveston
ClinicalTrials.gov Identifier: NCT00580151     History of Changes
Other Study ID Numbers: 04-101
IFFA ( Other Identifier: International Firefighters Association )
First Submitted: December 18, 2007
First Posted: December 24, 2007
Results First Submitted: February 8, 2013
Results First Posted: February 23, 2015
Last Update Posted: February 23, 2015